Business Context and Reporting Period
Rodgers Silicon Valley Acquisition Corp. (RSVA), a special purpose acquisition company, filed this Form 8-K on February 22, 2021, reporting its agreement to combine with Enovix Corporation, a battery technology company. The transaction would result in Enovix becoming a wholly owned subsidiary of RSVA, which would be renamed Enovix Corporation.
Transaction and Key Financial Terms
- RSVA agreed to acquire all outstanding Enovix equity for aggregate consideration of $1.05 billion, consisting of 105 million RSVA shares valued at $10.00 per share.
- RSVA entered into PIPE subscription agreements for 12.5 million shares at $14.00 per share, generating $175 million of gross proceeds.
- Transaction closing requires RSVA to receive at least $150 million of PIPE proceeds and have at least $175 million of cash on hand after redemptions and transaction expenses.
- RSVA must also maintain at least $5,000,001 of net tangible assets immediately after closing and redemptions.
- No revenue, profit, cash-flow, margin, debt, or balance-sheet results for RSVA or Enovix are reported in this filing.
Material Changes Versus the Prior Comparable Period
The filing does not present period-to-period operating or financial comparisons. The material development is the execution of the proposed business combination and related $175 million PIPE financing.
- RSVA’s post-closing board is expected to have no more than nine directors, with three designated by RSVA and six by Enovix.
- RSVA’s existing executive officers will resign at closing, and Enovix’s executive officers will assume the corresponding positions.
- RSVA and Enovix directors, officers, and certain stockholders entered into or agreed to enter into voting support and lock-up arrangements.
Guidance, Outlook, Risks, and Conditions
The filing contains forward-looking statements regarding the proposed transaction, Enovix’s expected growth, development and production milestones, revenue opportunities, operating performance, and anticipated benefits. These statements are not assurances of future performance.
Closing remains subject to stockholder and regulatory approvals, expiration of the Hart-Scott-Rodino waiting period, Nasdaq listing approval, minimum cash and net tangible asset requirements, execution of specified registration and lock-up agreements, and the absence of a material adverse effect on Enovix.
- The merger agreement may be terminated if closing has not occurred by July 31, 2021, if required approvals are not obtained, or under other specified circumstances.
- Completion depends on the PIPE financing and the level of RSVA stockholder redemptions.
- Other identified risks include failure to meet development or production targets, COVID-19 effects, competition, growth-management challenges, employee retention, transaction costs, legal proceedings, regulatory changes, and uncertainty in Enovix’s projected financial information.
- Enovix insiders’ lock-ups generally range from 90 days to 12 months, with certain releases tied to a $14.00 share-price condition or a change of control.
Important Facts for Investors to Verify
- Whether RSVA stockholders approve the transaction and whether all other closing conditions are satisfied.
- Whether the $175 million PIPE closes and the required minimum cash thresholds are achieved after redemptions and expenses.
- The final fully diluted capitalization and exchange ratio used to convert Enovix shares, options, and warrants.
- Enovix’s historical and projected revenue, cash burn, profitability, production capacity, development milestones, and funding requirements, which are not provided in this 8-K text.
- The definitive Form S-4/proxy materials, including transaction-related dilution, risk factors, financial statements, and management projections.
- Nasdaq approval and the timing of the business combination, including any amendments to the merger agreement.